tm logo
Live/Registered
REGISTERED

on 05 Apr 2022

Last Applicant/ Owned by

555 Twin Dolphin Drive, Suite 120

Redwood City

CA

94065

Serial Number

88143123 filed on 04th Oct 2018

Registration Number

6694536 registered on 05th Apr 2022

in the Principal Register

Correspondent Address

Michelle D. Kahn

Sheppard Mullin

Four Embarcadero Center, 17th Floor

San Francisco, CA 94111

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

Logo Mark Trademark Information

The mark consists of a stylized circle made of circles of varying size. Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocularRead More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; pharmaceuticals designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics


First Use Date in General

18th Feb 2022

First Use Date in Commerce

18th Feb 2022

Class [042]
Computer & Software Services & Scientific Services


Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and basic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents


First Use Date in General

18th Feb 2022

First Use Date in Commerce

18th Feb 2022

Mark Details


Serial Number

No 88143123

Mark Type

No Service Mark

Attorney Docket Number

No 73ZY-332866

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.01.21 -

Circles that are totally or partially shaded

26.01.31 -

Five or more circles

Description of Design Search

The mark consists of a stylized circle made of circles of varying size.

Legal History


Show more

Status DateAction Taken
05th Apr 2022REGISTERED-PRINCIPAL REGISTER
26th Feb 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
25th Feb 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
22nd Feb 2022STATEMENT OF USE PROCESSING COMPLETE
18th Feb 2022USE AMENDMENT FILED
18th Feb 2022TEAS STATEMENT OF USE RECEIVED
23rd Oct 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22nd Oct 2021EXTENSION 5 GRANTED
22nd Oct 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
14th Oct 2021EXTENSION 5 FILED